The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Vaccines: past, present and future
Open accessAbstract
The vaccines developed over the first two hundred years since Jenner's lifetime have accomplished striking reductions of infection and disease wherever applied. Pasteur's early approaches to vaccine development, attenuation and inactivation, are even now the two poles of vaccine technology. Today, purification of microbial elements, genetic engineering and improved knowledge of immune protection allow direct creation of attenuated mutants, expression of vaccine proteins in live vectors, purification and even synthesis of microbial antigens, and induction of a variety of immune responses through manipulation of DNA, RNA, proteins and polysaccharides. Both noninfectious and infectious diseases are now within the realm of vaccinology. The profusion of new vaccines enables new populations to be targeted for vaccination, and requires the development of routes of administration additional to injection. With all this come new problems in the production, regulation and distribution of vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein
Ulmer, J. B., Donnelly, J. J., Parker, S. E., Rhodes, G. H., Felgner, P. L., Dwarki, V. J., Gromkowski, S. H., Deck, R. R., DeWitt, C. M., Friedman, A., et al. (1993) · Science · doi:10.1126/science.8456302 · Cited by 2,318
A Controlled Trial of a Human Papillomavirus Type 16 Vaccine
Koutsky, L. A., Ault, K. A., Wheeler, C. M., Brown, D. R., Barr, E., Alvarez, F. B., Chiacchierini, L. M., & Jansen, K. U. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020586 · Cited by 1,602
Generation of influenza A viruses entirely from cloned cDNAs
Neumann, G., Watanabe, T., Ito, H., Watanabe, S., Goto, H., Gao, P., Hughes, M., Perez, D. R., Donis, R., Hoffmann, E., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.9345 · Cited by 1,278
Immunotherapeutic uses of CpG oligodeoxynucleotides
Klinman, D. M. (2004) · Nature Reviews Immunology · doi:10.1038/nri1329 · Cited by 1,012
Regulatory T cells and mechanisms of immune system control
O'Garra, A., & Vieira, P. (2004) · Nature Medicine · doi:10.1038/nm0804-801 · Cited by 810
Human hepatitis B vaccine from recombinant yeast
McAleer, W. J., Buynak, E. B., Maigetter, R. Z., Wampler, D. E., Miller, W. J., & Hilleman, M. R. (1984) · Nature · doi:10.1038/307178a0 · Cited by 739
Cancer vaccines: between the idea and the reality
Finn, O. J. (2003) · Nature Reviews Immunology · doi:10.1038/nri1150 · Cited by 636
Schneerson, R., Barrera, O., Sutton, A., & Robbins, J. B. (1980) · The Journal of experimental medicine · doi:10.1084/jem.152.2.361 · Cited by 625
Protection of Mice Against the Lyme Disease Agent by Immunizing with Recombinant OspA
Fikrig, E., Barthold, S. W., Kantor, F. S., & Flavell, R. A. (1990) · Science · doi:10.1126/science.2237407 · Cited by 488
A controlled clinical trial of the efficacy of the hepatitis B vaccine (heptavax B): A final report
Szmuness, W., Stevens, C. E., Zang, E. A., Harley, E. J., & Kellner, A. (1981) · Hepatology · doi:10.1002/hep.1840010502 · Cited by 457
THE USE OF YELLOW FEVER VIRUS MODIFIED BY IN VITRO CULTIVATION FOR HUMAN IMMUNIZATION
Theiler, M., & Smith, H. H. (1937) · Journal of Experimental Medicine · doi:10.1084/jem.65.6.787 · Cited by 445
The evolutionary biology of viruses
H.Harvey, P. (1994) · Trends in Ecology & Evolution · doi:10.1016/0169-5347(94)90260-7 · Cited by 438
Belshe, R. B., Gruber, W. C., Mendelman, P. M., Cho, I., Reisinger, K., Block, S. L., Wittes, J., Iacuzio, D., Piedra, P., Treanor, J., et al. (2000) · The Journal of Pediatrics · doi:10.1016/s0022-3476(00)70097-7 · Cited by 431
Mikszta, J. A., Alarcon, J. B., Brittingham, J. M., Sutter, D. E., Pettis, R. J., & Harvey, N. G. (2002) · Nature Medicine · doi:10.1038/nm0402-415 · Cited by 398
Vaccination with genetically engineered allergens prevents progression of allergic disease
Niederberger, V., Horak, F., Vrtala, S., Spitzauer, S., Krauth, M.-T., Valent, P., Reisinger, J., Pelzmann, M., Hayek, B., Kronqvist, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404735101 · Cited by 376
Matriano, J. A., Cormier, M., Johnson, J., Young, W. A., Buttery, M., Nyam, K., & Daddona, P. E. (2002) · Pharmaceutical Research · doi:10.1023/a:1013607400040 · Cited by 373
Modlin, J. F., Arvin, A. M., Fast, P., Myers, M., Plotkin, S., & Rabinovich, R. (2004) · Clinical Infectious Diseases · doi:10.1086/421999 · Cited by 331
Self-citationLevin, M. J., Smith, J. G., Kaufhold, R. M., Barber, D., Hayward, A. R., Chan, C. Y., Chan, I. S. F., Li, D. J. J., Wang, W., Keller, P. M., et al. (2003) · The Journal of Infectious Diseases · doi:10.1086/379048 · Cited by 314
Mutants of Pertussis Toxin Suitable for Vaccine Development
Pizza, M., Covacci, A., Bartoloni, A., Perugini, M., Nencioni, L., De Magistris, M. T., Villa, L., Nucci, D., Manetti, R., Bugnoli, M., et al. (1989) · Science · doi:10.1126/science.2683073 · Cited by 312
Guirakhoo, F., Pugachev, K., Zhang, Z., Myers, G., Levenbook, I., Draper, K., Lang, J., Ocran, S., Mitchell, F., Parsons, M., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.9.4761-4775.2004 · Cited by 253
Immunologic correlates of protection induced by vaccination
PLOTKIN, S. A. (2001) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200101000-00013 · Cited by 242
Self-citationHohlfeld, R., & Wekerle, H. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404874101 · Cited by 239
Munoz, F. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00352-9 · Cited by 228
Horwitz, M. A., & Harth, G. (2003) · Infection and Immunity · doi:10.1128/iai.71.4.1672-1679.2003 · Cited by 201
Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12
BERNSTEIN, D. (1998) · Vaccine · doi:10.1016/s0264-410x(97)00210-7 · Cited by 196
Can successful vaccines teach us how to induce efficient protective immune responses?
Lambert, P.-H., Liu, M., & Siegrist, C.-A. (2005) · Nature Medicine · doi:10.1038/nm1216 · Cited by 187
Alphavirus vectors and vaccination
Rayner, J. O., Dryga, S. A., & Kamrud, K. I. (2002) · Reviews in Medical Virology · doi:10.1002/rmv.360 · Cited by 181
Lipopeptide vaccines—yesterday, today, and tomorrow
BenMohamed, L., Wechsler, S. L., & Nesburn, A. B. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00318-3 · Cited by 173
Forsyth, K. D., Campins-Marti, M., Caro, J., Cherry, J. D., Greenberg, D., Guiso, N., Heininger, U., Schellekens, J., Tan, T., von Konig Carl-Heinz, W., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/426020 · Cited by 173
Self-citationFattom, A. I., Horwith, G., Fuller, S., Propst, M., & Naso, R. (2004) · Vaccine · doi:10.1016/j.vaccine.2003.11.034 · Cited by 168
Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model
Kantak, K. M., Collins, S. L., Lipman, E. G., Bond, J., Giovanoni, K., & Fox, B. S. (2000) · Psychopharmacology · doi:10.1007/s002130050049 · Cited by 165
Immunotherapy for Alzheimer's disease
Gélinas, D. S., Silva, K. D., Fenili, D., George‐Hyslop, P. S., & McLaurin, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404866101 · Cited by 162
From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza
Wood, J., & Robertson, J. S. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro979 · Cited by 141
Markowitz, M. H., Jin, X., Hurley, A., Simon, V. R., Ramratnam, B., Louie, M. J., Deschenes, G. R., Murugappan Ramanathan, Jr., Barsoum, S., Vanderhoeven, J., et al. (2002) · The Journal of Infectious Diseases · doi:10.1086/342559 · Cited by 138
Huang, Y., Yang, Z., Kong, W., & Nabel, G. J. (2004) · Journal of Virology · doi:10.1128/jvi.78.22.12557-12565.2004 · Cited by 132
Delivering on the promise: HPV vaccines and cervical cancer
Schiller, J. T., & Davies, P. O. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro867 · Cited by 129
Mora, M., Veggi, D., Santini, L., Pizza, M., & Rappuoli, R. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02689-8 · Cited by 129
Progress in DNA‐based heterologous prime‐boost immunization strategies for malaria
Moore, A., & Hill, A. V. S. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00138.x · Cited by 127
Pox Americana: the great smallpox epidemic of 1775-82
(2002) · Choice Reviews Online · doi:10.5860/choice.39-4604 · Cited by 126
Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines.
Stanberry, L. R. (2004) · PubMed · Cited by 122
Robinson, H. L. (1997) · Vaccine · doi:10.1016/s0264-410x(96)00249-6 · Cited by 121
Towards the rational design of Th1 adjuvants
Moingeon, P. E., Haensler, J., & Lindberg, A. A. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00193-1 · Cited by 116
Influenza vaccines: present and future
Palese, P., & García‐Sastre, A. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15999 · Cited by 116
Hallez, S., Simon, P., Maudoux, F., Doyen, J., No�l, J.-C., Beliard, A., Capelle, X., Buxant, F., Fayt, I., Lagrost, A.-C., et al. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0501-4 · Cited by 110
Baker, C. J., Paoletti, L. C., Rench, M. A., Guttormsen, H., Edwards, M. S., & Kasper, D. L. (2004) · The Journal of Infectious Diseases · doi:10.1086/382193 · Cited by 109
Modified Vaccinia Ankara: Potential as an Alternative Smallpox Vaccine
McCurdy, L., Larkin, B. D., Martin, J. E., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/421266 · Cited by 95
Cultivation of Poliomyelitis Virus in Cultures of Human Foreskin and Embryonic Tissues.
Th, W., Robbins, F. C., & Enders, J. F. (1949) · Experimental Biology and Medicine · doi:10.3181/00379727-72-17359 · Cited by 92
Influenza vaccines: present and future
Palese, P., & García‐Sastre, A. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215999 · Cited by 92
Moingeon, P. E. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00372-8 · Cited by 88
Progress in the Development of Respiratory Syncytial Virus and Parainfluenza Virus Vaccines
Durbin, A. P., & Karron, R. A. (2003) · Clinical Infectious Diseases · doi:10.1086/379775 · Cited by 78
The prime-boost concept applied to HIV preventive vaccines.
Jl, E., & Plotkin, S. A. (1997) · PubMed · Cited by 67
Self-citationA recombinant subunit vaccine approach to HCMV vaccine development.
Spaete, R. R. (1991) · PubMed · Cited by 61
Serruto, D., Adu‐Bobie, J., Capecchi, B., Rappuoli, R., Pizza, M., & Masignani, V. (2004) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2004.03.024 · Cited by 58
Six Revolutions in Vaccinology
Plotkin, S. A. (2005) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000148933.08301.02 · Cited by 58
Self-citationTherapeutic cancer vaccines: Using unique antigens
Lewis, J. J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404839101 · Cited by 57
Buckner, C. M., Gines, L. G., Saunders, C. J., Vojtech, L. N., Srivastava, I. K., Gettie, A., Bohm, R. P., Blanchard, J., Barnett, S. W., Safrit, J. T., et al. (2004) · Virology · doi:10.1016/j.virol.2003.12.003 · Cited by 50
Jones, T., Allard, F., Cyr, S. L., et al. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00387-6 · Cited by 42
Vaccines for the prevention of diseases caused by potential bioweapons
Hassani, M., Patel, M. C., & Pirofski, L. (2004) · Clinical Immunology · doi:10.1016/j.clim.2003.09.010 · Cited by 31
Therapeutic vaccination against chronic viral infections
Vandepapelière, P. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00289-x · Cited by 29
Vaccine Therapies for the Prevention of Type 1 Diabetes Mellitus
Petrovsky, N., Silva, D. A. S., & Schatz, D. (2003) · Pediatric Drugs · doi:10.2165/00148581-200305090-00001 · Cited by 27
Byerly, C. R. (2002) · Reviews in American History · doi:10.1353/rah.2002.0026 · Cited by 21
(1982) · Europe PMC (PubMed Central) · Cited by 21
Mettens, P., & Monteyne, P. (2002) · British Medical Bulletin · doi:10.1093/bmb/62.1.175 · Cited by 15
Cited by
mTOR regulates memory CD8 T-cell differentiation
Araki, K., Turner, A. P., Shaffer, V. O., Gangappa, S., Keller, S. A., Bachmann, M. F., Larsen, C. P., & Ahmed, R. (2009) · Nature · doi:10.1038/nature08155 · Cited by 1,575
Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
Lal, H., Cunningham, A. L., Godeaux, O., Chlibek, R., Diez-Domingo, J., Hwang, S.-J., Levin, M. J., McElhaney, J. E., Poder, A., Puig-Barberà, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501184 · Cited by 1,454
Vaccine hesitancy, vaccine refusal and the anti-vaccine movement: influence, impact and implications
Dubé, E., Vivion, M., & MacDonald, N. E. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.964212 · Cited by 986
Kushnir, N., Streatfield, S. J., & Yusibov, V. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.10.083 · Cited by 587
Shi, Y., Wang, G., Cai, X.-P., Deng, J.-W., Zheng, L., Zhu, H.-H., Zheng, M., Yang, B., & Chen, Z. (2020) · Journal of Zhejiang University-SCIENCE B · doi:10.1631/jzus.b2000083 · Cited by 580
Metadata
- Authors
- Plotkin, S. A.
- Venue
- Nature Medicine
- Published
- 2005-04
- Volume
- 11
- Issue
- S4
- Pages
- S5-S11
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2034219960
- Cited by
- 592
- References
- 63
- FWCI
- 6.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.